And while these drugs are pretty dang effective for weight loss and chronic disease management, they are not a cure-all
What the evidence supports: BPC-157 consistently improves tendon healing outcomes in animal models across multiple tissue types and injury models TB-500 accelerates wound healing and tissue repair in preclinical studies with measurable improvements in re-epithelialization, collagen deposition, and angiogenesis GHK-Cu enhances collagen synthesis and modulates thousands of genes involved in tissue repair GHRP-2 shifts macrophage polarization favorably in a rotator cuff tear model Relaxin-2 eliminates capsular fibrosis in a frozen shoulder mouse model No significant toxicity has been identified in preclinical BPC-157 studies What remains uncertain: Whether animal study results translate to equivalent human outcomes for shoulder conditions specifically Optimal dosing for human shoulder injuries (all protocols are extrapolated from animal data and clinical observation) Long-term safety with repeated use Whether peptides meaningfully reduce rotator cuff retear rates after surgical repair in humans How peptide therapy compares to established treatments like PRP in controlled human studies Potential interactions with medications commonly used by shoulder pain patients What we need: Randomized controlled trials of BPC-157 and TB-500 for specific shoulder conditions in humans Head-to-head comparisons of peptide therapy versus established treatments Long-term safety data from monitored human use Standardized dosing protocols based on human pharmacokinetic data Studies combining peptides with rehabilitation to assess synergistic effects The preclinical evidence is compelling
The range of gallbladder complications linked to Ozempic spans from mild to life-threatening: Acute cholecystitis requiring emergency hospitalization and surgical intervention Cholelithiasis (gallstones) causing severe right upper quadrant pain, especially after fatty meals Biliary colic with episodes of intense pain lasting hours Choledocholithiasis where stones migrate to the common bile duct causing obstruction Ascending cholangitis, a life-threatening infection of the bile ducts Pancreatitis secondary to gallstone migration Post-cholecystectomy syndrome with ongoing digestive problems after gallbladder removal Increased surgical risks due to delayed gastric emptying affecting anesthesia safety FDA investigations revealed particularly concerning patterns, with 47% of acute cholecystitis cases developing within 90 days of starting Ozempic, suggesting an immediate and dramatic effect on gallbladder function
You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch
Circulation 119 , 30933100 (2009)
